The angiogenic effect of ONO-1301, a novel long-acting prostacyclin agonist loaded in PLGA microspheres prepared using different molecular weights of PLGA, in a murine sponge model

Drug Development and Industrial Pharmacy

Volumn 40, Issue 11, 2014, Pages 1435-1442

  Hazekawa, Mai ^a   Morihata, Kana ^a   Yoshida, Miyako ^a   Sakai, Yoshiki ^b   Uchida, Takahiro ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Angiogenesis; Hemoglobin; HGF; in vivo fluorescence imaging; Sustained release

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; HEMOGLOBIN; MICROSPHERE; POLYGLACTIN; POLYMER; PROSTACYCLIN DERIVATIVE; SCATTER FACTOR; ANGIOGENIC FACTOR; DELAYED RELEASE FORMULATION; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROSTACYCLIN; PYRIDINE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; ENCAPSULATION; FLUORESCENCE IMAGING; IMPLANT; IN VIVO STUDY; MODEL; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PLASMA; RAT; SINGLE DRUG DOSE; SPONGE IMPLANT; SUSTAINED DRUG RELEASE; VASCULAR DISEASE; AGONISTS; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG RELEASE; MALE; MEDICINAL CHEMISTRY; MOUSE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG LIBERATION; EPOPROSTENOL; LACTIC ACID; MALE; MICE; MICROSPHERES; MOLECULAR WEIGHT; PARTICLE SIZE; POLYGLYCOLIC ACID; PYRIDINES; RATS;

EID: 84911463118     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.828220     Document Type: Article

References (28)

1. Second European consensus document on chronic critical leg ischemia. Circulation 1991;84:IV-1-26
2. Feedman S, Isner JM. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001;33:379-93
3. Tanouchi T, Kawamura M, Ohyama I, et al. Highly selective inhibitors of thromboxane synthetase 2 Pyridine derivatives. J Med Chem 1981;24:1149-55
4. Kataoka M, Nagaya N, Satoh T, et al. A long-Acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med 2005;172:1575-80
5. Obata H, Sakai Y, Ohnishi S, et al. Single injection of a sustainedrelease prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med 2008;177:195-201
6. Murakami S, Nagaya N, Itoh T, et al. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2006;290:59-65
7. Sakai Y, Nishiura A, Ogata T. WO 2004/032965 (2002), US7, 547, 715B2 (2009), Japanese Patent No. 4497320 (2010
8. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hind limb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2000;8:181-9
9. Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998;97:381-90
10. Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in Diabetes. Circulation 2001;104:2344-50
11. Morishita R, Sakai M, Yamamoto K, et al. Impairment of collateral formation in Lp(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation 2002;105:1491-6
12. Nakamura K, Sata M, Iwata H, et al. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischemic heart. Clin Sci 2007;112: 607-16
13. Iwata H, Nakamura K, Sumi M, et al. Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Life Sci 2009;85:255-61
14. Uchida T, Hazekawa M, Morisaki T, et al. Effect of antioxidants on the stability of ONO-1301, a novel long-Acting prostacyclin agonist, loaded in PLGA microspheres. J Microencapsul 2013;30:245-56
15. Kiff PS, Bergman G, Atkinson L, et al. Haemodynamic and metabolic effects of dazoxiben at rest and during atrial pacing. Br J Clin Pharmacol 1983;15:73-7
16. Hazekawa M, Sakai Y, Yoshida M, et al. Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity. J Pharm Pharmacol 2011;63:362-8
17. Hazekawa M, Sakai Y, Yoshida M, et al. Single injection of ONO-1301-loaded PLGA microspheres directly after ischemia reduces ischemic damage in rats subjected to middle cerebral artery occlusion. J Pharm Pharmacol 2012; 64:353-9
18. Hazekawa M, Sakai Y,Yoshida M, et al. The effect of treatment with a sustained-release prostacyclin analog (ONO-1301-loaded PLGA microspheres) on short-Term memory impairment in rats with transient global cerebral ischemia. J Microencapsul 2012; 29:211-18
19. Majima M, Isono M, Ikeda Y, et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn J Pharmacol 1997;75:105-14
20. Muramatsu M, Katada J, Hayashi I, Majima M. Chymase as a proangiogenic factor. A possible involvement of chymase-Angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000;275:5545-52
21. Campos PP, Bakhle YS, Andrade SP. Mechanisms of wound healing responses in lupus-prone New Zealand White Mouse strain. Wound Repair Regen 2008;16:416-24
22. Parrilha GL, Vieira RP, Campos PP, et al. Coordination of lapachol to bismuth (III) improves its anti-inflammatory and anti-Angiogenic activities. Biometals 2012;25:55-62
23. Majima M, Hayashi I, Muramatsu M, et al. Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-9
24. Okada H, Toguchi H. Biodegradable microspheres in Drug delivery. Crit Rev Ther Drug Carrier Syst 1995;12:1-99
25. Hu DE, Hiley CR, Smither RL, et al. Correlation of 133Xe clearance, blood flow and histology in the rat sponge model for angiogenesis. Further studies with angiogenic modifiers. Lab Invest 1995;72:601-10
26. Machado RD, Santos RA, Andrade SP. Opposing actions of angiotensins on angiogenesis. Life Sci 2000;66:67-76
27. Ozeki T, Hashizawa K, Kaneko D, et al. Treatment of rat brain tumors using sustained-release of camptothecin from poly (lactic-coglycolic acid) microspheres in a thermoreversible hydrogel. Chem Pharm Bull 2010;58:1142-7
28. Heya T, Okada H, Ogawa Y, Toguchi H. Factors influencing the profiles of TRH release from copoly (d,l-lactic/glycolic acid) microspheres. Int J Pharm 1991;72:199-205